Weekly Analysts’ Ratings Updates for Insmed (INSM)

Several brokerages have updated their recommendations and price targets on shares of Insmed (NASDAQ: INSM) in the last few weeks:

• 8/12/2024 – Insmed had its price target lowered by analysts at Truist Financial Co. from $88.00 to $85.00. They now have a “buy” rating on the stock.
• 8/12/2024 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
• 8/9/2024 – Insmed was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 8/9/2024 – Insmed had its price target raised by analysts at TD Cowen from $75.00 to $98.00. They now have a “buy” rating on the stock.
• 8/9/2024 – Insmed had its price target raised by analysts at UBS Group AG from $78.00 to $84.00. They now have a “buy” rating on the stock.
• 8/9/2024 – Insmed had its price target raised by analysts at Stifel Nicolaus from $74.00 to $88.00. They now have a “buy” rating on the stock.
• 7/12/2024 – Insmed had its price target raised by analysts at Morgan Stanley from $60.00 to $85.00. They now have an “overweight” rating on the stock.
• 7/10/2024 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $102.00. They now have a “buy” rating on the stock.
• 7/9/2024 – Insmed had its price target raised by analysts at Guggenheim from $70.00 to $95.00. They now have a “buy” rating on the stock.
• 7/8/2024 – Insmed had its price target raised by analysts at HC Wainwright from $70.00 to $90.00. They now have a “buy” rating on the stock.
• 7/5/2024 – Insmed had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $83.00 price target on the stock.
• 7/2/2024 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 7/1/2024 – Insmed had its price target raised by analysts at Truist Financial Co. from $68.00 to $88.00. They now have a “buy” rating on the stock.
• 6/28/2024 – Insmed had its price target raised by analysts at Bank of America Co. from $62.00 to $83.00. They now have a “buy” rating on the stock.
• 6/21/2024 – Insmed had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an “outperform” rating on the stock.
• 6/20/2024 – Insmed had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 6/20/2024 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an “overweight” rating on the stock.

Insmed Price Performance

Shares of INSM traded up $1.39 during trading hours on Monday, hitting $77.59. The company’s stock had a trading volume of 2,238,778 shares, compared to its average volume of 2,492,424. The business has a 50 day simple moving average of $70.64 and a two-hundred day simple moving average of $44.01. The company has a market cap of $11.53 billion, a price-to-earnings ratio of -14.84 and a beta of 1.16. Insmed Incorporated has a 52-week low of $21.21 and a 52-week high of $78.87.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. The firm’s revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.78) EPS. Research analysts predict that Insmed Incorporated will post -4.71 earnings per share for the current year.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $55.00, for a total transaction of $1,165,725.00. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at $5,837,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Insmed news, insider John Drayton Wise sold 7,852 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $49.79, for a total value of $390,951.08. Following the transaction, the insider now directly owns 121,657 shares in the company, valued at approximately $6,057,302.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $55.00, for a total transaction of $1,165,725.00. Following the transaction, the insider now owns 106,134 shares in the company, valued at $5,837,370. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 249,611 shares of company stock worth $12,584,876. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INSM. Rafferty Asset Management LLC grew its stake in shares of Insmed by 17.4% in the 4th quarter. Rafferty Asset Management LLC now owns 321,087 shares of the biopharmaceutical company’s stock valued at $9,950,000 after buying an additional 47,563 shares during the period. Kingdon Capital Management L.L.C. purchased a new position in shares of Insmed in the 4th quarter valued at $12,551,000. Artia Global Partners LP purchased a new position in Insmed during the 4th quarter worth $2,322,000. Norges Bank purchased a new position in Insmed during the 4th quarter worth $45,029,000. Finally, Clearbridge Investments LLC acquired a new stake in shares of Insmed in the 1st quarter worth $25,242,000.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.